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Abstract: Background: Inflammation is considered as a predictor of cardiovascular diseases in type
2 diabetes mellitus. No previous studies have investigated the effect of low glycemic index (LGI)
recipes of South Indian cuisine on the risk factors of cardiovascular disease in patients with diabetes.
Aim: The aim of this randomized controlled trial was to evaluate the improvement in cardiovascular
risk factors and blood glucose control, in patients with type 2 diabetes, after intervention with recipes
of Kerala cuisine, from locally available whole grain cereals, low in glycemic index. Method: This was
a prospective and randomized controlled study that was conducted over a period of 24 weeks. A total
of 80 participants were recruited from the Department of Endocrinology and Diabetes Outpatient in
Kerala, South India. All 80 patients had type 2 diabetes, and were aged between 35 and 65 years.
Participants were randomly assigned and advised to follow either a LGI diet plan (n = 40) or their
usual diet, which served as a control group (n = 40). The advice was reinforced throughout the study
period. Anthropometric, biochemical parameters which included glycemic and cardio-metabolic
parameters were measured according to standard procedures. T-tests were conducted to compare
the differences between intervention and control groups, and the Pearson correlation coefficient
was used to evaluate associations between the variables. Results: There were significant differences
(p < 0.05) between the intervention and control groups with respect to weight, HbA1c, insulin,
triglycerides, Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), high sensitivity
C-reactive protein (hs-CRP) and apolipoprotein B (ApoB). There was also a positive correlation
between weight and blood glucose variables. ApoB was positively correlated with lipid profile and
insulin levels. Conclusions: The long-term implementation of LGI diet of Kerala cuisine has been
found to promote weight loss, enhance insulin sensitivity and reduce the cardiovascular risk.
Keywords: low GI diet; south Indian (Kerala) cuisine; hs-CRP; HOMA-IR; ApoB; glycemic control
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1. Introduction
Diabetes mellitus is a well-established risk factor for cardiovascular disease, and an increased
incidence of coronary artery disease and cardiovascular mortality has been strongly associated with
the presence of metabolic syndrome [1] This linkage has been corroborated by the notably higher
morbidity and mortality rate in patients with diabetes compared to non-diabetic individuals. Besides,
metabolic syndrome has been reported to be a predictor of subclinical atherosclerosis. Some of the
factors associated with the increased risks of cardiovascular disease in diabetes mellitus are higher
levels of low density lipoprotein (LDL) cholesterol, elevated blood pressure, lower levels of high
density lipoprotein (HDL) cholesterol, insulin resistance, hyperglycemia, inflammation, hypertension,
dyslipidemia and obesity [2]. Vascular dysfunction resulting from type 2 diabetes has been shown as
the causative factor for cardiovascular disease [3].
Inflammatory-response proteins are considered as predictors of cardiovascular events. C-reactive
protein (CRP) is defined as a sensitive, but non-specific marker of inflammation [4]. The atherosclerotic
process is now considered as an inflammatory disease. Compared to other ethnic groups, South Asian
community is highly vulnerable to higher mortality rates from coronary heart disease (CHD) and
stroke. Among Asians, incidence of CHD, 5–10 years earlier, have been ascribed to lower HDL, higher
triglyceride and higher LDL levels and higher blood pressure (BP). Furthermore, a strong correlation
has been found between diabetes and higher rates of heart failure (HF) and all-cause death (ACD) [5].
Higher incidences of cardiovascular (CVD) complications in the Asian population with type 2 diabetes
mellitus (T2DM) calls for systematic treatment strategies tailored to Asian ethnicity [6].
Cereals are the staple diet of South Indians and carbohydrate constitutes about 55–65% of their
daily intake of calories. There has been a transition in the quality of grains consumed from whole
grains to highly polished grains. Consumption of whole grains is highly recommended unlike refined
grains, which comprise endosperm that are known to stimulate adverse effect on the cardio-metabolic
risk factors including diabetes [7]. Ingestion of high carbohydrate diets can raise blood glucose, insulin
and triglycerides, leading to insulin resistance. Glycemic index (GI), which gauge the quality of
carbohydrates, is considered as an important factor in the management of non-communicable diseases,
particularly type 2 diabetes. Glycemic index is a relative ranking of carbohydrate in foods according to
how they affect blood glucose levels. Carbohydrates with a low GI value (55 or less) are more slowly
digested, absorbed and metabolized and cause a lower and slower rise in blood glucose and, therefore,
insulin levels. High glycemic index foods(>70) have been shown to trigger rapid increase in the
post-prandial blood sugar and insulin [8] and have shown to increase the risk of type 2 diabetes mellitus
and CVD [9,10] in the western population as well as in Asian population, specifically Indians [11] and
Chinese [12].
Traditional Indian diets are rich in dietary fiber, which could explain the lower incidence of type
2 diabetes mellitus in India in the 1960s–1970s. Studies in western countries have shown that the
replacement of refined grains with whole grains have resulted in risk mitigation of type 2 diabetes and
CVD in hyperinsulinemic and impaired glucose tolerant patients.
In our previous study [13] that investigated the effect of a low GI (LGI) diet with local recipes
of South Indian, Kerala cuisine on body composition and glycemic control in people with diabetes,
it was demonstrated that there was a significant reduction (p < 0.05) of truncal obesity and glycated
hemoglobin. However, there is minimal published testimony that shows the efficacy of long-term
intervention, triggered by smaller changes in the intake of traditional red rice and whole wheat flour
that is low in glycemic index for the risk reduction of CVD in South Indians with type 2 diabetes.
The current study is a follow up component of a larger study directed to assess the improvement in
cardiovascular risk factors and blood glucose control among type 2 diabetes subjects, pursuant to a
24-week dietary consumption of Kerala cuisine from locally available LGI whole grain cereals.
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1.1. Objectives of this study:
Primary Objective
• To compare the reductions in glycated hemoglobin (HbA1c) after 24 weeks of intervention with
LGI diet
1.2. Secondary Objectives
• To examine changes in blood lipids and blood pressure in the intervention group on LGI diet,
compared to the regular diet.
• To evaluate changes in inflammatory markers such as hs-CRP and apolipoprotein B (ApoB)
between the LGI and control group.
• To measure reduction in fasting insulin and Homeostatic Model Assessment of Insulin Resistance
(HOMA-IR) in the study groups, after intervention with the diet.
• To observe effects of LGI diet in reducing obesity and abdominal obesity
• To correlate weight changes and cardiovascular risk factors in subjects with type 2 diabetes
2. Methodology
The study was a single-centered, controlled trial, where randomized sampling technique was
used to recruit the subjects. Every third patient with type 2 diabetes who visited the Dietitian in the
Department of Endocrinology and Diabetes (OP), Amrita institute of Medical Sciences and Research
Centre, Kerala, India was screened and assigned at random to either the interventional or the control
group. A total of 120 patients were randomized into either LGI group or control group.
Study duration: The study was conducted between October 2018 and April 2019 for a period
of 24-weeks.
Inclusion criteria: Subjects with history of type 2 diabetes aged between 35 and 65 years, of both
genders with HbA1c in the range of 7 to 10%, who were managed by stable doses of antidiabetic
medications for at least 3 months prior to enrolment, and had no history of CVD, were included in the
study. Patients on antihypertensive and/or cholesterol lowering medications were also managed by
stable doses of these medications for at least 3 months prior to enrolment. All medications remained
unchanged during the whole study.
Exclusion criteria: Subjects with chronic diabetes >10 years; other diabetes associated complications
such as diabetic retinopathy, nephropathy, neuropathy; conditions like cancer, chronic renal failure;
chronic cardiovascular ailments such as chronic cardiac failure or subjects having triple vessel disease
or double vessel disease requiring surgical management; subjects who have undergone major surgeries
and conditions like psychiatric illness or malabsorption syndromes were excluded from the study
group. After screening, informed consent was obtained from all the study participants. The study was
approved by the institutional ethics committee.
2.1. Sample Size
A pilot study was conducted to estimate the minimum sample size. Since there was no published
paper in the existing literature covering foods of Kerala cuisine and cardiovascular risk factors in type
2 diabetes, a pilot study was performed with 20 subjects each in the LGI diet group and the control
group. Based on the primary objective variable, HbA1c(%), the mean difference in LGI group was
−1.13 ± 0.27 and control group was 0.4 ± 0.25, with 80% power and 95% confidence, and the minimum
sample size was found to be 16 in each group. Among a total of 120 subjects with type 2 diabetes,
only 80 participants completed the study, 40 in each group. This sample size will yield >90% power
and 99% confidence for the comparison.
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2.2. Study Procedures
Anthropometric measurements which included height, weight, BMI, waist circumference,
hip circumference and blood samples were taken at baseline and after 6 months. Height was
measured without shoes, to the nearest 0.1 cm, using a stadiometer; weight was measured by a
calibrated weighing scale to the nearest 0.1 kg. BMI was calculated and interpreted according
to the Asian classification: normal (18.5–22.9 kg/m2), overweight (23.0–24.9 kg/m2), Obese class I
(25.0–29.9 kg/m2) and Obese class II (>30.0 kg/m2) [14].
Waist circumference was measured to the nearest 0.5 cm between the iliac crest and the lowest rib
at the narrowest point just above the hip bone; hip circumference was measured around the maximum
circumference of the buttocks using an inch tape.
Blood pressure was measured with the subject in the seated position using a sphygmomanometer;
a consistent value above 130/80 mmHg was considered to be hypertensive according to the New
ACC/AHA high blood pressure guidelines (2019) [15].
2.3. Biochemical Analysis
A blood sample for fasting blood glucose was collected after 8 to 12 h of fasting in a grey vacutainer
containing an anticoagulant and a stabilizer, i.e., EDTA, and sodium fluoride and postprandial blood
glucose samples were collected in another grey vacutainer 2 h after meal. Whole blood was collected
in a violet vacutainer coated with EDTA K2 for the estimation of glycated hemoglobin (HbA1c).
The blood sample for analyzing fasting lipid profiles, fasting insulin and ApoB were collected
using green vacutainer coated with lithium heparin, ammonium heparin or sodium heparin.
HOMA-IR was calculated as fasting insulin (U/L) × fasting glucose (mg/dL)/405, as described by
Matthews et al. [16].
The blood samples were spun immediately after sampling; the plasma collected, refrigerated
and stored at −20 ◦C until all the patients completed the study. All samples were estimated using the
Roche autoanalyzer, at the central laboratory of Amrita Institute of Medical Sciences and Research
Centre, tertiary care hospital accredited by the National Accreditation Board of Testing and Calibration
Laboratories (NABL). The interpretation of the blood glucose profile was assessed according to
American Diabetes Association (ADA) guidelines 2017, and the reference interval for lipids was
appraised per National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report [17].
2.4. Dietary Intervention
The dietary assessment was done in all the study subjects. The quality and quantity of the
consumed diet was assessed by using food frequency questionnaire and 24-h dietary recall method,
respectively. Macronutrient composition of the consumed diet was calculated from the 24-h dietary
recall using Nutritive value of Indian Foods. The Food Frequency Questionnaire (FFQ) included 60
food items commonly consumed in Kerala. The frequency of food intake was recorded as either daily,
weekly, monthly, occasionally and never. The compliance to LGI ingredients in the intervention group
was assessed from the FFQ when the subjects came for follow up.
The control group was advised to consume their usual diet. The LGI group was advised to
consume a diet plan prescribed with LGI recipes prepared with traditional foods of Kerala cuisine as
shown in Table 1. This advice was reinforced by the Dietitian throughout the study period.
2.5. Follow Up
The subjects were followed up by telephone for verification of dietary compliance; they were
evaluated by a 24 h dietary recall at weeks 3, 11, 12, 18, 23 and 24. During the pre-scheduled telephone
interviews, the foods consumed by the subject in the preceding 24 h were recalled, and noted. The subjects
were asked to come for an in-personal visit to the hospital at week 24 to reassess the anthropometric
and biochemical parameters, and the periodically recorded data was statistically analyzed.
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Table 1. The diet plan for the low glycemic index (LGI) diet group.
Breakfast
Red rice puttu (GI = 38)
Whole wheat flour (GI = 45) puttu
Rolled oats/Steel cut oats puttu (GI = 51/52)
Lunch Rose Matta rice (GI = 38)
Dinner
Broken wheat (GI = 41) upma
Broken wheat + green gram + fenugreek seeds kanji (porridge)
Whole wheat flour (GI = 45) roti
2.6. Outcomes
Primary outcomes for this study were the effect of LGI diet on HbA1c after 24 weeks of intervention.
Secondary outcomes include changes in blood pressure, lipid profile, fasting insulin, HOMA-IR,
ApoB, hs-CRP, body weight and waist circumference after 24 weeks of intervention.
2.7. Ethics
This study was approved by the Institutional Ethics Committee of Amrita Institute of Medical
Sciences and Research Centre, reference number IEC-AIMS-2018-DIET-165, and registered under
Clinical Trials Registry-India (ICMR-NIMS), CTRI Reg No.: CTRI/2019/12/022425.
2.8. Statistical Analysis
Descriptive analyses were used to describe the study sample; Chi-square and/or t-test analysis
was used to compare the socio-demographic characteristics of the study population. Differences in
demographic characteristics were deduced using the χ2 test for categorical variables, and nonparametric
Wilcoxon test was applied for continuous variables. Paired sample Student’s t-test was used to compare
the baseline and week 24 within the intervention group and the control group. The independent
Student’s t-test was used to compare differences between the intervention and control groups. The mean
± SD difference between the baseline and week 24 for all variables was also calculated. The Pearson
correlation coefficient was leaned on to detect associations between the study variables. All statistical
analyses were performed using IBM SPSS 20.0 for Windows (SPSS Inc., Chicago, IL, USA). All the
statistical tests were based on two-tailed hypothesis tests, where the significance level was defined as
p < 0.05.
3. Results
Table 2 presents a summary of the demographic data of the study participants. In both the
intervention and control groups, the mean ages were comparable. Social habits such as smoking,
which is a major risk factor for CVD, was not observed in more than 90% of the subjects. Majority
of the study participants were engaged primarily in mild physical activity. Comorbidities, such as
dyslipidemia and hypertension, were seen in more than 50% of the study subjects. History of CVD
and thyroid diseases was seen only in very small fraction of the participants, as shown in Table 2.
Table 3 shows the baseline characteristics of the study variables in both groups. Anthropometric
variables and blood glucose profile were comparable at baseline between the groups. Statistically
significant difference was observed in LDL between the study groups, all other biochemical variables
were comparable at baseline. The nutrient intake showed significant difference in caloric intake
between the groups. However the percentage of carbohydrate, protein and fat were comparable.
Int. J. Environ. Res. Public Health 2020, 17, 6232 6 of 17
Table 2. Demographics of the study participants.
LGI (n = 40) Control (n = 40)
Age 54.43 ± 7.57 51.93 ± 7.43
Gender
Male 25 (62.5%) 27 (67.5%)
Female 15 (37.5%) 13 (32.5%)
Social habits
Smoking
Yes 4 (10%) 3 (7.5%)
No 36 (90%) 37 (92.5%)
Physical activity
Sedentary 6 (15%) 4 (10%)
Mild 21 (52.5%) 25 (62.5%)
Moderate 13 (32.5%) 11 (27.5%)
Comorbidities
DLP 22 (55%) 25 (62.5%)
HTN 23 (57.5%) 23 (57.5%)
CAD 11 (27.5%) 6 (15%)
Thyroid 5 (12.5%) 2 (5%)
DLP, dyslipidemia; HTN, hypertension; CAD, coronary artery disease.
Table 3. Comparison of the baseline characteristics of the study subjects.
Variable LGI Group (n = 40) Control Group (n = 40) p Value
Blood Pressure
Systolic BP (mm Hg) 132.9 ± 15.37 131.10 ± 13.28 0.577
Diastolic BP (mm Hg) 79.90 ± 12.32 81.35 ± 8.45 0.541
Anthropometric measurement
Height (cm) 161.46 ± 7.51 163.98 ± 6.69 0.118
Weight (kg) 69.12 ± 10.78 72.26 ± 10.52 0.191
BMI (kg/m2) 26.40 ± 3.03 26.75 ± 3.29 0.623
Waist circumference (cm) 95.34 ± 8.92 96.29 ± 8.99 0.631
Biochemical variables
FBS (mg/dL) 155.46 ± 36.10 150.01 ± 48.65 0.571
PPBS (mg/dL) 227.21 ± 43.18 223.17 ± 48.53 0.695
HbA1c (%) 8.44 ± 0.96 8.27 ± 0.99 0.443
Insulin (mIU/L) 31.70 ± 46.61 28.65 ± 58.38 0.796
HOMA-IR 11.62 ± 14.63 8.99 ± 13.61 0.408
Total cholesterol (mg/dL) 172.43 ± 34.84 163.42 ± 41.76 0.298
Triglycerides (mg/dL) 147.54 ± 63.20 131.30 ± 42.96 0.183
HDL (mg/dL) 42.48 ± 10.12 41.82 ± 10.48 0.775
LDL (mg/dL) 119.60 ± 32.13 104.50 ± 34.99 0.048 *
VLDL (mg/dL) 27.52 ± 10.75 27.95 ± 12.87 0.872
hsCRP (mg/L) 3.38 ± 3.83 2.79 ± 4.20 0.517
ApoB (mg/dL) 94.44 ± 22.81 88.14 ± 24.61 0.239
Nutrient intake
Calories 1554.8 ± 233.25 1430.4 ± 182 0.010 **
Carbohydrate (%) 15.71 ± 2.44 15.75 ± 2.09 0.940
Protein (%) 64.62 ± 5.56 63.30 ± 6 0.313
Fat (%) 22.6 ± 5.88 24.3 ± 5.37 0.181
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Table 3. Cont.
Variable LGI Group (n = 40) Control Group (n = 40) p Value
Medications
Sulfonylureas 24 28
Metformin 33 42
DPP4-inh 15 20
Insulin 13 17
Acarbose 2 0
Meglitinides (Repaglinide) 1 0
Statins 20 26
Antihypertensives 22 20
Notes: BP, blood pressure; BMI, body mass index; FBS, fasting blood sugar; PPBS, postprandial blood sugar;
HbA1c, glycated hemoglobin; HOMA-IR, homeostatic model assessment of insulin resistance; HDL, high density
lipoprotein; LDL, low density lipoprotein; VLDL, very low density lipoprotein; hsCRP, high sensitivity C-reactive
protein; ApoB, apolipoprotein-B. * (p < 0.05); ** (p < 0.01)
Table 4 shows the post-intervention changes in all the variables under study. There was a significant
reduction in the anthropometric measurements such as weight, BMI and waist circumference. In the
LGI group, weight reduced by 1.87 kg and waist circumference reduced by 2.94 cm, whereas not much
difference was observed in the control group. The changes observed in the blood glucose profile after
intervention were the reduction in fasting and post-prandial blood sugar by 21 mg/dL and 37.87 mg/dL
in the LGI diet group, respectively. These changes affected the improvement in HbA1c by 0.93% in
the LGI group, which was highly significant compared to the control group. The insulin resistance
improved significantly in the intervention group which has shown to reduce the inflammatory markers
such as hs-CRP and other cardiovascular risk factors, particularly triglycerides, LDL and ApoB in
subjects on LGI diet. The lipid profile and triglycerides showed a highly significant reduction of
26.89 mg/dL in the LGI group compared to an increase in the values in the control group. The total
cholesterol and HDL though showed an improvement in the control group were not statistically
significant. However, the systolic blood pressure, which is considered an important risk factor toward
the prediction of CVD, had shown an insignificant reduction in the intervention group compared to
no change in the control group. The diastolic pressure also showed no significant change. Overall,
there were significant differences (p < 0.05) between the LGI and control groups with respect to weight,
glycated hemoglobin, insulin, Homa-IR, triglycerides, hs-CRP and ApoB. In contrast, differences
between the two groups were not significant (p > 0.05) in relation to systolic and diastolic blood
pressure, BMI, waist circumference, fasting blood glucose, postprandial blood glucose, total cholesterol,
HDL, LDL and VLDL.
Table 4. Comparison of mean ± SD of the variables at baseline and 24 weeks after intervention
between groups.
Variable Group Baseline 24 Weeks MeanDifference p Value
p Value (LGI vs.
Control) at
24 Weeks
Blood Pressure
Systolic pressure
(mmHg)
LGI 132.90 ± 15.32 130.35 ± 17.63 −2.55 ± 16.6 0.337
0.683Control 131.1 ± 13.28 131.83 ± 14.43 0.72 ± 14.84 0.759
Diastolic pressure
(mmHg)
LGI 79.9 ± 12.32 77.63 ± 7.08 −2.27 ± 12.67 0.263
0.068Control 81.35 ± 8.45 80.60 ± 7.29 −0.75 ± 6.96 0.500
Anthropometric
measurements
Weight (kg) LGI 69.12 ± 10.78 67.25 ± 9.81 −1.87 ± 2.63 0.000 ** 0.020 *Control 72.26 ± 10.52 72.79 ± 11.00 0.53 ± 1.96 0.094
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Table 4. Cont.
Variable Group Baseline 24 Weeks MeanDifference p Value
p Value (LGI vs.
Control) at
24 Weeks
BMI (kg/m2)
LGI 26.40 ± 3.03 25.71 ± 2.77 −0.70 ± 0.99 0.000 **
0.078Control 26.75 ± 3.29 26.95 ± 3.42 0.20 ± 0.70 0.083
Waist circumference
(cm)
LGI 95.34 ± 8.92 92.40 ± 8.99 −2.94 ± 4.71 0.000 **
0.148Control 96.29 ± 8.99 95.45 ± 9.64 −0.84 ± 4.47 0.244
Biochemical
parameters
FBS (mg/dL) LGI 155.46 ± 36.10 136.75 ± 27.54 −21.21 ± 39.42 0.001 ** 0.192Control 150.01 ± 48.65 146.63 ± 38.73 −3.38 ± 34.57 0.540
PPBS (mg/dL) LGI 227.21 ± 43.18 189.33 ± 56.49 −37.87 ± 59.36 0.000 ** 0.063Control 223.17 ± 48.53 212.22 ± 52.13 −10.94 ± 51.44 0.186
HbA1c (%) LGI 8.44 ± 0.96 7.52 ± 0.94 −0.93 ± 0.92 0.000 ** 0.003 **Control 8.27 ± 0.99 8.27 ± 1.20 0.012 ± 0.87 0.929
Insulin (mIU/L) LGI 31.70 ± 46.61 14.79 ± 15.89 −16.91 ± 40.42 0.012 * 0.030 *Control 28.65 ± 58.38 33.57 ± 51.17 4.92 ± 57.67 0.592
HOMA-IR
LGI 11.62 ± 14.63 5.10 ± 6.06 −6.51 ± 12.11 0.002 **
0.017 *Control 8.99 ± 13.61 10.83 ± 13.50 1.84 ± 15.76 0.464
Total Cholesterol
(mg/dL)
LGI 172.43 ± 34.84 159.12 ± 33.68 −13.30 ± 37.37 0.030 *
0.422Control 163.42 ± 41.76 152.97 ± 34.41 −10.45 ± 31.77 0.044 *
Triglycerides
(mg/dL)
LGI 147.54 ± 63.20 120.65 ± 44.80 −26.89 ± 48.37 0.001 **
0.025 *Control 131.30 ± 42.96 153.06 ± 77.60 21.76 ± 56.69 0.020 *
HDL (mg/dL) LGI 42.48 ± 10.12 41.92 ± 11.22 −0.56 ± 5.64 0.531 0.886Control 41.82 ± 10.48 42.27 ± 10.50 0.44 ± 6.86 0.683
LDL (mg/dL) LGI 119.60 ± 32.13 105.02 ± 26.80 −14.57 ± 27.42 0.002 ** 0.979Control 104.50 ± 34.99 104.85 ± 33.13 0.34 ± 28.44 0.939
VLDL (mg/dL) LGI 27.52 ± 10.75 25.62 ± 11.24 −1.90 ± 10.28 0.249 0.254Control 27.95 ± 12.87 28.79 ± 13.34 0.84 ± 9.71 0.588
hs-CRP (mg/L) LGI 3.38 ± 3.83 1.46 ± 1.04 −1.92 ± 3.83 0.003 ** 0.026 *Control 2.79 ± 4.20 3.16 ± 4.61 0.36 ± 3.21 0.479
ApoB (mg/dL) LGI 94.44 ± 22.81 81.88 ± 19.83 −12.55 ± 19.50 0.000 ** 0.007 **Control 88.14 ± 24.61 95.05 ± 22.27 6.90 ± 16.15 0.010 **
Nutrient intake
Calories (kcal) LGI 1430.4 ± 182 1511 ± 137.5 80.6 ± 243 0.043 * 0.010 **Control 1554.8 ± 233.3 1450.4 ± 157.1 104.4 ± 250.1 0.012
Protein (g) LGI 55.8 ± 8.49 61.8 ± 10.1 6.02 ± 14.95 0.015 * 0.025 *Control 61.3 ± 12.8 58.5 ± 11.7 −2.88 ± 8.15 0.221
Carbohydrate (g) LGI 230.9 ± 33.9 232.7 ± 28.4 1.85 ± 47.11 0.807 0.081Control 245.1 ± 37.5 238.4 ± 26.4 −6.69 ± 46.2 0.365
Fat (g) LGI 36.1 ± 10.4 40.9 ± 7.71 1.77 ± 7.47 0.036 * 0.019 *Control 42.4 ± 12.7 34.2 ± 10.1 −8.15 ± 17.2 0.005 **
BMI, body mass index; FBS, fasting blood sugar; PPBS, postprandial blood sugar; HbA1c, glycated hemoglobin;
HOMA-IR, homeostatic model assessment of insulin resistance; HDL, high density lipoprotein; LDL, low density
lipoprotein; VLDL, very low density lipoprotein; hsCRP, high sensitivity C-reactive protein; ApoB, apolipoprotein-B.
* (p < 0.05); ** (p < 0.01)
Table 5 shows the comparison of macronutrient intake after 24 weeks of intervention. The protein
intake remained unchanged in both groups throughout the study period. There was a significant
difference in the percentage of carbohydrate intake and fat intake between the groups.
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Table 5. Comparison of the percentage of the macronutrient intake between baseline and 24 weeks
after dietary intervention in the study groups.
Nutrient Intake Baseline 24 Weeks p Value
Calories (kcal) LGI 1430.4 ± 182 1511 ± 137.5
0.07Control 1554.8 ± 233.3 1450.4 ± 157.1
Protein (%) LGI 15.71 ± 2.44 16.38 ± 2.44
0.571Control 15.75 ± 2.09 16.07 ± 2.53
Carbohydrate (%) LGI 64.62 ± 5.56 61.6 ± 4.62
<0.001 **Control 63.3 ± 6 65.93 ± 5.14
Fat (%) LGI 22.6 ± 5.88 24.37 ± 3.9
0.003 **Control 24.3 ± 5.37 21.12 ± 5.4
** (p < 0.01)
Figure 1a depicts the anthropometric measurements showing a significant weight loss in the LGI
group compared to an increase in the control group. There were reductions in fasting and postprandial
blood glucose in both intervention and control groups, with a greater reduction observed in the LGI
group as shown in Figure 1b. The fasting insulin and insulin resistance, as measured by HOMA-IR
shown in Figure 1b, was significantly reduced in LGI group, whereas the same parameter saw an
increase in the control group. In contrast to the results obtained in the LGI diet group, there was an
increase in all these cardiovascular variables in the control group as presented in Figure 1c.
Correlation of Weight and Cardiovascular Risk Factors Postintervention in the Study Groups
Association of weight and ApoB with the study variables: Weight was found to be strongly
associated with various study variables (Figure 2a–d). A strong positive correlation was observed with
waist circumference, whereas a negligible association was found with postprandial blood sugar and
HbA1c as depicted in Table 6. Moderate correlations were observed with ApoB and total cholesterol
and LDL (Table 7). There was a negligible correlation with fasting insulin levels at the end of the
intervention period (Table 7).
Table 6. Correlation between weight and other study variables after 24 weeks of diet intervention.
Table 4 Variables Weight p Value
Pearson Correlation Coefficient (r)
Waist circumference 0.735 ** <0.01
Postprandial blood sugar 0.251 * <0.05
HbA1c 0.241 * <0.05
* (p < 0.05); ** (p < 0.01).
Table 7. Correlation between apolipoprotein-B and other study variables after 24 weeks of
diet intervention.
Variables ApoB p Value
Pearson Correlation Coefficient (r)
Total Cholesterol 0.529 ** <0.01
Triglycerides 0.314 ** <0.01
LDL 0.599 ** <0.01
Fasting Insulin 0.237 * <0.05
* (p < 0.05); ** (p < 0.01).
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Figure 1. (a)—The mean difference in the anthropometric measurements; (b)—biochemical
variables—blood glucose levels and insulin resistance; and (c)—lipid profile and cardiovascular
biomarkers after a 24-week diet intervention between the groups. BMI, body mass index; FBS, fasting
blood sugar; PPBS, postprandial blood sugar; HbA1c, glycated hemoglobin; HOMA-IR, homeostatic
model assessment of insulin resistance; HDL, high density lipoprotein; LDL, low density lipoprotein;
VLDL, very low density lipoprotein; hsCRP, high sensitivity C-reactive protein; ApoB, apolipoprotein-B;
LGI, low glycemic Index. * Denotes significant difference.
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Figure 2. Cont.
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Figure 2. Correlation of weight with anthropometric and biochemical parameters: (a) The correlation of
weight with WC (waist circumference); (b) PPBS (postprandial blood sugar); (c) HbA1c after 24 weeks
of dietary intervention. (d) Correlation of apolipoprotein B with fasting insulin after 24 weeks of
dietary intervention.
4. Discussion
The key findings in this randomized controlled trial after 24 weeks intervention with LGI recipes of
South Indian Kerala cuisine were significant improvements in glycated hemoglobin and cardiovascular
Int. J. Environ. Res. Public Health 2020, 17, 6232 13 of 17
risk factors such as hs-CRP, fasting insulin, HOMA-IR, triglycerides and weight in the intervention
group compared with the control group and non-significant reductions in systolic blood pressure,
total cholesterol and HDL.
In this intervention study, there was a significant reduction in HbA1c by 0.93% in the LGI group.
The UKPDS35 prospective observational study showed that each 1% reduction in HbA1c was associated
with a 14% reduction of the relative risk of myocardial infarction [18]. Similarly, the efficacy of a
nutritionist-delivered low-GI dietary intervention, with the support of a personal digital assistant
(PDA), for adult patients with poorly controlled type II diabetes showed a 0.5% decrease in HbA1c [19].
A study which compared LGI diet with high-cereal fiber diet in type 2 diabetes subjects for a period
of 6 months showed a moderately lower HbA1c levels in the intervention group [20]. A 12-week
intervention with LGI energy restricted diet in type 2 diabetics did not show any improvement in
glycemic control [21]. However, in another study that compared LGI diet and standard diabetic diet,
there was no statistically significant difference between the diets in relation to HbA1c and fasting blood
glucose [22]. The longer duration of 24 weeks of LGI intervention could be the factor responsible for
the better outcome in relation to glycated hemoglobin in this study.
The LGI diet in our study group had a favorable effect on 2-h post prandial blood sugar compared
to the control group, albeit the differences were not significant (p > 0.05) between the two groups.
This is an important finding in T2DM, because high postprandial blood sugar is shown to be a better
indicator of CVD risk than fasting blood sugar [23]. Changes in 2-h post prandial blood sugar could be
due to changes in insulin sensitivity, which was observed in this study.
This investigation has drawn attention to other metabolic parameters that contribute to the
development of CVD risks in patients with type 2 diabetes. For example, fasting insulin and HOMA-IR
were noticeably reduced after the 24-week intervention. In contrast to our findings, an intervention
with energy restricted LGI diet in 62 overweight women for 6 months did not show any changes in
HOMA-IR [24]. Insulin resistance as evaluated by HOMA-IR is considered to be a good predictor for
CVD [25]. Elevated risk of CVD observed in insulin resistance is due to the overproduction of reactive
oxygen species and advanced glycation end products, which aggravate the low-grade inflammation.
Insulin Resistance Atherosclerosis Study (IRAS) showed a direct relation between insulin resistance
and atherosclerosis [26].
The present study showed a remarkable difference in serum triglyceride between the low GI
and the control groups confirming the findings of a previous study done by Omprakash et al. [27],
which reported that a very LGI diet notably abated serum triglycerides in 40 subjects. In contrast,
randomized controlled trial performed by Salwa et al. [28] revealed that LGI diet did not show any
noteworthy drops in triglyceride levels in type 2 diabetic males. The HDL cholesterol levels, however,
remained unchanged in our study. This observation was similar to the findings in other studies [29–31].
Hence, the LGI diet of Kerala cuisine is considered safe as the HDL levels did not drop. On the other
hand, CRP is a clinical marker of low grade inflammation and this may underlie an increased CV risk
known as residual inflammatory index, recently described for patients with type 2 diabetes. Residual
Inflammatory Risk (RIR) is defined as persistent circulating levels of hs-CRP > 2mg/L despite an optimal
(<70 mg/dL) control of LDL cholesterol and represents an emerging risk factor for the development
of cardiovascular events in patients at high risk for atherosclerosis. In our study, the intervention
with LGI recipes of Kerala cuisine showed a significant reduction in hs-CRP from 3.3 to 1.4 mg/dL
indicating a reduction in RIR, and this reduction can prevent coronary atherosclerosis. A similar
observation was seen in the Aggrastat to Zocor (A to Z) trial, which demonstrated that best clinical
outcomes occurred when the hsCRP levels were lowered below 2 mg/L in conjunction with lowering
LDL-C to < 70 mg/dL [32]. A recent study showed that 39.2% of patients with type 2 diabetes had RIR
and the findings suggested that glycemic control, insulin resistance, non-LDL-C lipid variables and
central obesity are implicated in RIR in patients with type 2 diabetes even with well-controlled LDL-C
levels [33]. These findings support the observations that patients with high inflammatory burden
could achieve an hs-CRP <2 mg/L by lifestyle modifications alone [34].
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A study done by Jenkins et al. [20] showed that type 2 diabetes subjects who were on high-fiber
cereal foods over a duration of 6 months did not show lowered CRP levels. An investigation by
Saburo et al. showed high hs-CRP levels in the metabolic diabetic group, significantly higher than
non-metabolic diabetic group, indicating the metabolic syndrome subjects who develop type 2 diabetes
are at further risk for coronary artery disease (CAD) [1]. The hsCRP measure has been known to have
opsonizing properties, increasing the recruitment of monocytes into atheromatous plaque, and inducing
endothelial dysfunction by suppression of releases of basal and induced nitric oxide. hsCRP per se has
also been found to increase the expression of vascular endothelial plasminogen activator inhibitor-1
(PAI-1) and other adhesion molecules and alter LDL uptake by macrophages [35].
ApoB has been associated with increased coronary artery disease, while LGI diets have been
shown to significantly reduce the risk. Findings of this research have affirmed that ApoB was associated
with total cholesterol, triglycerides and LDL, but no correlation was observed between ApoB and
HDL. Similar observations were recorded by Prabita et al. [36] where ApoB was correlated with total
cholesterol, triglycerides, VLDL and LDL. However, HDL was negatively correlated in that study.
In the same study, the median serum apolipoprotein B-100 level was significantly higher in diabetes
with cardiovascular complications than without complications. In the present study, it was observed
that serum ApoB levels had a significant positive correlation with fasting insulin. In a cross-sectional
study of 2834 subjects from the Framingham Offspring cohort, GI was shown to be positively associated
with the prevalence of the metabolic syndrome and insulin resistance [37]. Insulin resistance, which is
a prominent feature of T2DM, may be one of the factors responsible for elevated apolipoprotein B-100
levels in our study subjects. In their study, Jiang’s team [38] confirmed that apo B concentration
was significantly higher in diabetic men with cardiovascular complications than in diabetic men
without complications.
Our study showed that the LGI preparations of Kerala cuisine had a significant impact on
glycemic control and weight loss in the sampled population. It has been proposed that the glycemic
index of foods can influence body-weight control [39]. Low-GI foods may also delay the return of
hunger by slowing gastric emptying. The LGI preparations of Kerala cuisine, which are high in fiber,
promote greater satiety by prolonging the distension of the gastrointestinal tract, causing increased and
prolonged secretion of the gut peptides cholecystokinin, ghrelin, glucagons, glucagons-like-peptid-1,
and glucose-dependent insulinotropic polypeptide, all of which have been suggested as potential
satiety factors compared to other cuisine [40].
This paper, in essence, is the first prospective study, with prolonged follow up, on the effect of
LGI Kerala cuisine on glycemic and cardiovascular risk factors. Strict adherence to prescribed diet
was ensured by meticulous telephonic follow up. Incorporation of LGI local recipes and traditional
ingredients was the highlight of the study that assured unrelented compliance to the diet regimen.
Limitations of the Study
The dropout rates in the LGI group were high compared to the control group. The reasons put
forth, for the withdrawal from the study, were poor compliance to the diet, during social gatherings
and travel. Besides, few women, recruited for the study, refused to visit the hospital without a
personal escort.
5. Conclusions
The inclusion of LGI diets of Kerala cuisine is an effective strategy of alleviating cardiovascular
risk factors in patients with type 2 diabetes. In particular, the long-term implementation of LGI diet
of Kerala cuisine has been found to control blood sugar and has been found to promote weight loss,
enhance insulin sensitivity and minimize cardiovascular risk.
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